Genomic sequencing analysis of 733 HER2-amplified Most important and metastatic breast tumours disclosed significant enrichment of mutations that activate RAS–MAPK signalling in Superior tumours addressed with prior anti-HER2 therapies121. These mutations, which include NF1 and HER2 activating mutations, contribute to resistance to tucatinib and neratinib. White women during the U.S. https://www.directivepublications.org/journal-of-clinical-breast-cancer/